WallStSmart

Nektar Therapeutics (NKTR)vsRevolution Medicines Inc (RVMD)

VS

Smart Verdict

WallStSmart Research — data-driven comparison

Nektar Therapeutics generates 7398% more annual revenue ($55.63M vs $742,000). RVMD leads profitability with a 0.0% profit margin vs -284.2%. NKTR earns a higher WallStSmart Score of 34/100 (F).

NKTR

Avoid

34

out of 100

Grade: F

Growth: 3.3Profit: 2.0Value: 6.7Quality: 6.5
Piotroski: 3/9Altman Z: -18.92

RVMD

Avoid

24

out of 100

Grade: F

Growth: 3.7Profit: 3.0Value: 5.0Quality: 6.0
Piotroski: 1/9Altman Z: -0.99

Key Strengths & Concerns

Side-by-side fundamental analysis

Key Strengths

NKTR3 strengths · Avg: 9.0/10
PEG RatioValuation
0.3110/10

Growing faster than its price suggests

Debt/EquityHealth
0.259/10

Conservative balance sheet, low leverage

Price/BookValuation
2.5x8/10

Reasonable price relative to book value

RVMD1 strengths · Avg: 9.0/10
Debt/EquityHealth
0.109/10

Conservative balance sheet, low leverage

Areas to Watch

NKTR4 concerns · Avg: 3.3/10
Revenue GrowthGrowth
3.8%4/10

3.8% revenue growth

EPS GrowthGrowth
0.0%4/10

0.0% earnings growth

Piotroski F-ScoreQuality
3/93/10

Weak financial health signals

Return on EquityProfitability
-53.6%2/10

ROE of -53.6% — below average capital efficiency

RVMD4 concerns · Avg: 3.3/10
EPS GrowthGrowth
0.0%4/10

0.0% earnings growth

Profit MarginProfitability
0.0%3/10

0.0% margin — thin

Operating MarginProfitability
0.0%3/10

Operating margin of 0.0%

Piotroski F-ScoreQuality
1/93/10

Weak financial health signals

Comparative Analysis Report

WallStSmart Research

Bull Case : NKTR

The strongest argument for NKTR centers on PEG Ratio, Debt/Equity, Price/Book. PEG of 0.31 suggests the stock is reasonably priced for its growth.

Bull Case : RVMD

The strongest argument for RVMD centers on Debt/Equity.

Bear Case : NKTR

The primary concerns for NKTR are Revenue Growth, EPS Growth, Piotroski F-Score.

Bear Case : RVMD

The primary concerns for RVMD are EPS Growth, Profit Margin, Operating Margin.

Key Dynamics to Monitor

NKTR profiles as a turnaround stock while RVMD is a value play — different risk/reward profiles.

RVMD carries more volatility with a beta of 1.41 — expect wider price swings.

NKTR is growing revenue faster at 3.8% — sustainability is the question.

NKTR generates stronger free cash flow (-44M), providing more financial flexibility.

Bottom Line

NKTR scores higher overall (34/100 vs 24/100). Both earn "Avoid" and "Avoid" ratings respectively — the choice depends on your investment horizon and risk tolerance.

This analysis is generated from publicly available financial data. Not financial advice.

Nektar Therapeutics

HEALTHCARE · BIOTECHNOLOGY · USA

Nektar Therapeutics is a biopharmaceutical company. The company is headquartered in San Francisco, California with additional operations in Huntsville, Alabama and Hyderabad, India.

Revolution Medicines Inc

HEALTHCARE · BIOTECHNOLOGY · USA

Revolution Medicines, Inc., a precision clinical-stage oncology company, is focused on developing therapies to inhibit borderline targets in RAS-addicted cancers. The company is headquartered in Redwood City, California.

Want to dig deeper into these stocks?